Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

Beyfortus reached blockbuster status in its first full year, with sales of €1.7 billion ($1.77 billion) in 202410.

In Q3 2024, Beyfortus brought in nearly $700 million, representing a 381% year-over-year increase1.

Sanofi expects Q4 Beyfortus sales to be similar to Q3, implying full-year 2024 sales of approximately €1.5 billion1.

The strong performance of Beyfortus contributed to a 25% year-over-year growth in Sanofi's vaccines division1.

Beyfortus is now protecting babies in more than 20 countries7.

The US market is anticipated to have enough supply for every eligible baby to have access to immunization4.

Sanofi is collaborating with AstraZeneca on Beyfortus development and manufacturing, with new filling lines approved to expand supply4.

Beyfortus is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease in newborns and infants4.

The global Beyfortus market is expected to see significant growth in the coming years, driven by factors such as increasing RSV cases and rising awareness of respiratory diseases2 5.

Sanofi continues to work on expanding its vaccine pipeline, including RSV vaccines for adults and children, to complement Beyfortus10.